MEDICURE APPROVED TO INITIATE PHASE II/III HYPERTENSION TRIALS.

Medicure Inc. (TSX:MPH), Winnipeg, Canada, a cardiovascular drug discovery and development company, has received approval from Canada's Therapeutic Products Directorate (TPD) to commence a Phase II trial as part of the development program for Medicure's second clinical candidate, MC-4232. The initial patients are being enrolled in the first of a series of exploratory trials in hypertension.

Hypertension is a common disorder in which blood pressure remains abnormally high. Approximately 57 million adult North Americans have high blood pressure. Of those, 73% of them are